Disease · MONDO_0002462

glomerulonephritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. glomerulonephritis. Diseases, record MONDO_0002462. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002462

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: glomerulonephritis; Open Targets
Open Targets ID: MONDO_0002462; Open Targets
Other names: glomerular nephritis, glomerulonephritis (disease), nephritis of renal glomerulus, renal glomerulus nephritis; Open Targets
Disease Ontology: DOID:2921; Disease Ontology
MeSH: D005921; MeSH
NCI Thesaurus: C26784; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 18 drugs, from DailyMed; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
CHLOROTHIAZIDE	CHEMBL842	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CHLORTHALIDONE	CHEMBL1055	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LISINOPRIL ANHYDROUS	CHEMBL1237	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
SLC12A3	Solute carrier family 12 member 3	3	Thiazide-sensitive sodium-chloride cotransporter inhibitor	Approval	https://conductscience.org/library/genes/6559	Drugs and targets
CFB	Complement factor B	2	Complement factor B inhibitor	Unknown	https://conductscience.org/library/genes/629	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 2	https://conductscience.org/library/genes/1636	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 3	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 3	https://conductscience.org/library/genes/136	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	1	Type-1 angiotensin II receptor antagonist	Phase 2	https://conductscience.org/library/genes/185	Drugs and targets
CFD	Complement factor D	1	Complement factor D inhibitor	Phase 1	https://conductscience.org/library/genes/1675	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets

1 to 10 of 35

See all 35 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02197767	Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis	Phase 2	11	2019-02-06	Fibrillary Glomerulonephritis	RITUXIMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00424749	Rituxan in Churg Strauss Syndrome With Renal Involvement	Phase 2	4	2011-12-08	Churg-Strauss Syndrome	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00001256	Steroids and Methotrexate to Treat Systemic Vasculitis	Phase 2	100		Inflammation, Vasculitis, Wegener's Granulomatosis	METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00354731	Efficacy of Pentoxifylline on Primary Nephrotic Syndrome	Phase 3	62		Nephrotic Syndrome	PENTOXIFYLLINE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT05283057	Empagliflozin in Patients With Glomerulonephritis	Phase 3	50		Glomerulonephritis, Proteinuria	EMPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT00914524	Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy	Phase 2	49		Chronic Glomerulonephritis, Diabetic Nephropathy	OLMESARTAN MEDOXOMIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT07038382	A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis	Phase 2	24		Membranous Nephropathy, Lupus Nephritis (LN)	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02682459	ACE-inhibitors in Extracapillary Glomerulonephritis	Phase 2	22		Extracapillary Glomerulonephritis	LISINOPRIL ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT00154661	Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis	Not applicable	20		Primary Glomerulonephritis	PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov
NCT06295770	Obinutuzumab in Treatment of Fibrillary Glomerulonephritis	Phase 2	20		Fibrillary Glomerulonephritis	OBINUTUZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21325353	RESULT	1	PubMed
32617582	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002462

GET https://conductscience.org/api/diseases/v1/MONDO_0002462/targets?page=2

API reference For AI assistants